Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)
A Phase 2B Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy
Sponsor: PTC Therapeutics
Listed as NCT00592553, this PHASE2 trial focuses on Becker Muscular Dystrophy and Duchenne Muscular Dystrophy and remains completed. Sponsored by PTC Therapeutics, it has been updated 10 times since 2008, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
May 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — May 2020 [monthly]
Completed PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE2
Phase: PHASE2_PHASE3 → PHASE2
-
Aug 2017 — Dec 2017 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Feb 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PTC Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aurora, United States, Barcelona, Spain, Boston, United States, Calgary, Canada, Cincinnati, United States, Dallas, United States, Durham, United States, Essen, Germany, Freiburg im Breisgau, Germany, Gothenburg, Sweden and 26 more location s